Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Head-to-head evidence comparison — which supplement is right for you?
Omega-3 wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
15 of 23 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
4 of 5 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Omega-3 and Piracetam have evidence — compare verdict strength side-by-side.
2-3g combined EPA+DHA daily
With meals containing fat
Triglyceride form fish oil
1200-4800mg daily in divided doses
Divided into 2-3 doses, Morning and early afternoon, With a choline source
Piracetam powder or capsules
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
2-4 weeks
1-2 weeks
Ongoing
First few days
Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial
Nature communications (2025) · Meta analysis · n=5205
Mean body mass index (BMI) was 27.5 kg/m2 (SD = 5.3), with 51% female and 17% Black race/ethnicity.
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
The present systematic review and meta-analysis indicate the efficacy of omega-3 FAs in increasing the serum concentration of BDNF.
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Piracetam for reducing the incidence of painful sickle cell disease crises
The Cochrane database of systematic reviews (2016) · Meta analysis · n=169
Although there was no significant difference between the piracetam and placebo periods for the number of days of hospitalisation (P = 0.87) in one trial, inconsistencies in the criteria necessary for hospitalisation during sickle crises did not permit accurate conclusions to be drawn.
Treatment Efficacy of Pharmacotherapies for Frontotemporal Dementia: A Network Meta-Analysis of Randomized Controlled Trials
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry (2023) · Meta analysis · n=243
Compared with placebo, high-dose oxytocin (72 international units) was associated with the greatest improvement in patients' neuropsychiatric symptoms (SMD = -1.17, 95% CIs = -2.25 to -0.08, z = -2.10, p = 0.035).
Based on multiple meta-analyses showing EPA-dominant formulas >1g/day most effective. Effects plateau around 2-2.5g. Adjunctive use with antidepressants shows better outcomes than monotherapy.
Based on meta-analysis of 1002 stroke patients, but showed non-significant increase in death at one month. Evidence is limited and mixed. Conservative effectiveness estimates due to safety concerns.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 9/10) and wins in 1 of 3 categories.
For sharpen focus, Piracetam has a higher relevance score (75 vs 70).
No known interactions between Omega-3 and Piracetam have been documented in our database. However, always consult a healthcare provider before combining supplements.